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https://doi.org/10.1016/j.omtm.2019.10.013.Age-related macular degeneration (AMD) is a progressive
retinal disorder characterized by imbalanced pro- and
antiangiogenic signals. The aim of this study was to evaluate
the effect of ex vivo cell-based gene therapy with stable expres-
sion of human pigment epithelium-derived factor (PEDF)
release using the non-viral Sleeping Beauty (SB100X) trans-
poson system delivered byminiplasmids free of antibiotic resis-
tance markers (pFAR4). Retinal pigment epithelial (RPE) cells
and iris pigment epithelial (IPE) cells were co-transfected with
pFAR4-inverted terminal repeats (ITRs) CMV-PEDF-BGH
and pFAR4-CMV-SB100X-SV40 plasmids. Laser-induced
choroidal neovascularization (CNV) was performed in rats,
and transfected primary cells (transfected RPE [tRPE] and
transfected IPE [tIPE] cells) were injected into the subretinal
space. The leakage and CNV areas, vascular endothelial growth
factor (VEGF), PEDF protein expression, metalloproteinases 2
and 9 (MMP-2/9), and microglial/macrophage markers were
measured. Injection with tRPE/IPE cells significantly reduced
the leakage area at 7 and 14 days and the CNV area at 7 days.
There was a significant increase in PEDF and the PEDF/
VEGF ratio with tRPE cells and a reduction in the MMP-2
activity. Our data demonstrated that ex vivo non-viral gene
therapy reduces CNV and could be an effective and safe thera-
peutic option for angiogenic retinal diseases.14Senior author
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Choroidal neovascularization (CNV) occurs mainly as a conse-
quence of the imbalance between pro and antiangiogenic factors,
such as vascular endothelial growth factor (VEGF) and pigment
epithelium-derived factor (PEDF), respectively.1,2 This imbalance
is the hallmark of several retinal pathologies including the neovas-Molecular Therapy: Methods & Clin
This is an open access article under the CC BY-NC-cular form of age-related macular degeneration (AMD), high
myopia,3 and proliferative diabetic retinopathy.4 AMD is the lead-
ing cause of irreversible severe vision loss and legal blindness in
adults over 55 years of age in developed countries.5–7 It is estimated
that 196 million individuals will be affected with AMD by 2020,
which is a health and social problem, especially for the elderly
population.8,9
Currently, there is no cure for AMD, and the therapy for the neovas-
cular form is focused at controlling the CNV on inhibiting VEGF
levels by disrupting the angiogenic cascade by frequent (almost
monthly) intravitreal injections of anti-VEGF antibodies, which
have considerable costs,10,11 thereby representing a serious public
health issue.12 Repeated doses of anti-VEGFs are usually needed for
several years, because cessation may result in the recurrence of
CNV.13 Although VEGF antagonists have been shown to be safe,14
side effects mainly related to the injection have been detected.15
Moreover, given that VEGF is an essential factor for cell survival,16
it has been suggested that repeated exposure to VEGF antagonists
may damage retinal neurons.17,18 Therefore, novel strategies are
developed aiming to achieve an antiangiogenic status by means otherical Development Vol. 15 December 2019 ª 2019 The Authors. 403
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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ing repeated injections.
Because reduction of PEDF levels is linked to the pathogenesis of neo-
vascular AMD, PEDF treatment is beneficial to treat this degenerative
disorder. Exogenously administered PEDF provides potent antiangio-
genic activity by directly inhibiting proliferation of endothelial cells
and/or inducing their death through both extrinsic and intrinsic
apoptotic pathways.1,2,19 PEDF has demonstrated to have anti-in-
flammatory properties, by decreasing the expression of pro-inflam-
matory factors such as the tumor necrosis factor-a (TNF-a) as shown
in a rat model of retinopathy.20 In addition, PEDF also exhibits
antioxidant properties, as well as broad neurotrophic effects.21–23
However, the half-life of PEDF is 6 h, and thus even shorter than
currently used anti-VEGF molecules,24 which makes it incapable of
offering an alternative to currently required repeated injections. In or-
der to solve the problems generated by the requirement of frequent
injections, due to the transient expression of the therapeutic PEDF,
several strategies are currently in development for reducing treatment
burden. These include antiangiogenic gene therapies with adeno-
associated viruses (AAVs), small-molecule drugs, facilitating higher
concentrations and potentially longer duration than current anti-
VEGF agents, and sustained-release anti-VEGF delivery systems
such as the ranibizumab Port Delivery System, GB-102, NT-503, hy-
drogel depot, Durasert, and ENV1305.25
Alternatively, we pursue a gene therapy approach based on non-viral
gene delivery of the antiangiogenic PEDF into cells isolated from the
eye by the integrating Sleeping Beauty (SB) transposon system
(recently reviewed by Narayanavari et al.,26 Kebriaei et al.,27 Hodge
et al.28 Hudecek et al.,29 and Hudecek and Ivics30). In a previous pilot
study, we observed that transplantation of SB-engineered rat retinal
pigment epithelial (rRPE) cells and rat iris pigment epithelial (rIPE)
cells expressing PEDF seemed to reduce the development of new ves-
sels by almost 50% in a rat model of CNV.31 Although the time win-
dow available to study changes after RPE and IPE cell transplanta-
tions is limited using the laser-induced CNV model,32–34 this model
is highly suitable to study short-term angiogenesis, inflammation,
and proteolysis biomarkers. In the present study we investigated
the efficacy of the hyperactive SB100X transposase combined with
pFAR4 miniplasmids to transfect primary IPE or RPE cells at two
different doses to continuously release human PEDF (hPEDF) in an
established model of CNV in rats. We also aimed at determining
insertion sites and exploring histologically and biochemically
morphological alterations related to the angiogenic status after trans-
plantation of genetically modified primary cells secreting human anti-
angiogenic PEDF.
RESULTS
Localization of Transplanted Venus-Transfected Cells in the
Subretinal Space
First, we addressed whether genetic engineering of RPE and IPE cells
would compromise their biological properties. Using phase-contrast404 Molecular Therapy: Methods & Clinical Development Vol. 15 Decemmicroscopy, no changes in either cell morphology or pigmentation
were observed in rRPE (Figure S1A) and rIPE cells cultured ex vivo
(Figure S1F). Venus expression was observed after transfection with
pFAR4-inverted terminal repeats (ITRs)-CAGGS Venus plasmid in
rRPE cells (Figures S1B–S1D) and rIPE cells (Figures 1G–1I).
Cultured rRPE cells were positive for RPE65 (Figure S1E) and rIPE
cells for CK18 antibodies (Figure S1J). Following transplantation
into the subretinal space of experimental rats, automated digital (Fig-
ures 1A and 1B) and confocal microscope (Figures 1C–1N) were used
to confirm the localization and survival of transfected RPE (tRPE)
and transfected IPE (tIPE) cells expressing the Venus fluorescent re-
porter protein at 1 week post-injection. To confirm that the Venus
cells were the injected ones, we labeled transfected cells with CellBrite
(a plasmatic membrane marker) before injection (Figures 1G–1N).
We observed that SB-engineered cells maintained their cellular prop-
erties and identity, and survived in vivo following transplantation in
the eye.
PEDF and VEGFRelease bySB-EngineeredRat PrimaryRPE and
IPE Cells
Having established the basic parameters for gene delivery with the SB
transposon system, we addressed the biological properties of rRPE
and rIPE cells engineered with the hPEDF following transplantation
into the eyes of rats that had previously undergone laser-induced trig-
gering of CNV. To confirm that the PEDF detected was produced by
the plasmids (hPEDF), the pFAR4/ITRs CMV-PEDF-BGH and
pFAR4/ITRs CMV-PEDF-histidine (His)-BGH miniplasmids were
used to transfect the rat cells alongside with a source of the SB100X
transposase. Before injection into the subretinal space, the primary
cells were transfected with the construct pFAR4-ITRs CMV PEDF-
His BGH plasmid in order to identify the transplanted cells with
PEDF and His tag. We detected engineered PEDF-His reporter-ex-
pressing RPE and IPE cells using anti-PEDF (mouse monoclonal,
MAB1059, 1:1,000; Chemicon) and anti-His antibodies (6-His, goat
polyclonal, NBP1-25939, 1:400; Novus, Cambridge, UK) (Figures
2A–2E). Moreover, retinal homogenates showed that gene expression
of rat PEDF (rPEDF) mRNA was similar in saline and the RPE-
PEDF-SB groups as expected (Figure 2F), although gene expression
of rPEDF mRNA in IPE cells showed a significant increase in the
5,000 tIPE-PEDF-SB group versus saline (Figure 2G) (p < 0.05). Spe-
cific hPEDF mRNA was detectable only in tRPE/tIPE-PEDF-SB cells
and not in the saline-treated control group. The hPEDF increase was
highly significant in the 10,000 PEDF-SB group (p < 0.001) versus all
injected eyes in tRPE cell and tIPE cell groups compared with saline
(Figures 2H and 2I).
At the protein level, PEDF expression was significantly increased in
animals injected with 10,000 tRPE-PEDF-SB cells versus the saline
group (Figure 3A) (p < 0.05). However, no significant differences
were found in the tIPE-PEDF-SB and IPE-PEDF groups (Figure 3B).
Notably, rVEGF protein expression level was similar in the injected
tRPE/IPE-PEDF-SB and tRPE/IPE-PEDF animals (Figures 3C and
3D). Importantly, as a consequence of PEDF release by the engineered
cells, the antiangiogenic ratio (PEDF/VEGF) was significantlyber 2019
Figure 1. Fluorescence Representative Images of
Rat Primary Cells in the Subretinal Space after
Injection
(A) An automatic mosaic image of Venus-RPE cells (green)
in the rat subretinal space. (B) Detail of a group of Venus-
RPE cells in the RPE. (C–F) Confocal images of Venus-
RPE cells in subretinal area between RPE and ONL.
(C and D) Cells were transfected with the pFAR4-ITRs-
CAGGS Venus miniplasmid (green), and the nuclei were
stained with DAPI (blue). (E) Merged image from (C) and
(D). (F) Orthogonal projection of the injected Venus cells.
Arrows indicate Venus primary cells injected. (G) RPE cells
labeled with CellBrite (red) and DAPI (blue) in a super-
resolution image captured. (H–N) Confocal images of a
group of Venus-CellBrite-RPE cells in the subretinal space
near the RPE. Four RPE cells are represented (H–J) with
their orthogonal projection confocal images (K–N). Nuclei
are labeled with DAPI (blue). Scale bars: (A–F) 100 mm, (G)
20 mm, (H–N) 50 mm. CB, CellBrite; GCL, ganglion cell
layer; INL, inner nuclear layer; ONL, outer nuclear layer;
OS, outer segment; PEDF, pigment epithelium-derived
factor; RPE, retinal pigment epithelium.
www.moleculartherapy.orgincreased in 10,000 tRPE-PEDF-SB animals (Figure 3E) (p < 0.05)
versus the Saline group, whereas in the remaining groups no signifi-
cant changes were observed (Figure 3F). These data suggested that, as
a result of shifting the antiangiogenic ratio, PEDF-expressing cells
could affect angiogenesis and neovascularization.
Matrix metalloproteinase-2 (MMP-2) plays an important role in the
formation of new blood vessels and in endothelial cell migration, a
key feature of angiogenesis.35–37 Additionally, MMP-9 has also been
suggested to play a complex, indirect role in angiogenesis by pro-
moting VEGF mobilization.38 Importantly, previous studies have
indicated that MMPs play important roles in early AMD.35,39
Disequilibrium of the gelatinases suggests a role of abnormal extra-
cellular matrix metabolism that breaks through the basal membrane
into the sub-retinal space. Active MMP-2 and MMP-9 can induce
the proteolysis of PEDF in the extracellular matrix of the cell and
thus interfere with the antiangiogenic and neurotrophic activities
of the cellular PEDF protein.40–43 We found that MMP-2 activity
levels were significantly lower in eyes of rats injected with 10,000
RPE-PEDF-SB cells versus the saline group (Figure 3G) (p <
0.05), whereas no differences were observed in the IPE-PEDF-SB
and IPE-PEDF groups (Figure 3H). In addition, MMP-9 activity
levels were similar in all groups injected with RPE or IPE cells (Fig-
ures 3I and 3J).Molecular Therapy: Methods & ClinAntiangiogenic Effects Elicited by
SB-Engineered Rat Primary IPE and RPE
Cells Expressing hPEDF
In order to assess the effect of the hPEDF release
on vascular leakage, we used fluorescein angiog-
raphy (FA) at 7 and 14 days post-laser treat-
ment. We did not observe a decrease in the
percentage of the leakage area in animals in-jected with tRPE cells at 7 days (Figures 4A and 4C); however, a
statistically significant decrease of the leakage area was observed at
day 7 in the 10,000 tIPE-PEDF-SB group versus animals injected
with saline (p < 0.01; Figures 4B and 4D). Fourteen days post-laser
treatment, animals injected with 5,000 and 10,000 tRPE-PEDF-SB
cells showed a statistically significant decrease in the area of the fluo-
rescein leakage (Figures 4E and 4G) (p < 0.01). Similarly, animals in-
jected with 10,000 tIPE-PEDF-SB cells showed a significant decrease
in FA area (Figures 4F and 4H) (p < 0.01).
We measured the most important indicator of antiangiogenic effects,
the CNV areas at 7 and 14 days post-laser treatment, and a statistically
significant decrease in the percentage of CNV area in the 5,000
(p < 0.05) and 10,000 tRPE-PEDF-SB groups (p < 0.01) and in the
10,000 tRPE-PEDF group (p < 0.05) at the 7-day time point (Figures
4I and 4J) was observed. In IPE cells, we observed a statistically signif-
icant CNV area decrease in the 10,000 tIPE-PEDF-SB and 10,000
tIPE-PEDF groups (Figures 4K and 4L) (p < 0.05). These results indi-
cate that PEDF-engineered cells can elicit a measurable antiangio-
genic effect. This effect is especially pronounced in animals injected
with 10,000 tRPE-PEDF-SB cells, which also displayed the highest ra-
tio of PEDF over VEGF protein expression (Figures 3A and 3E). The
CNV area decreased in all experimental groups analyzed at 14 days
post-laser (with the exception of the 10,000 tRPE-PEDF group), butical Development Vol. 15 December 2019 405
Figure 2. Results of the rPEDF and hPEDF
Determination in Retinas Injected with tRPE and
tIPE Cells with PEDF-His and SB100X Plasmid
(A–E) Representative immunofluorescence images of the
tRPE cells colocalized with anti-His (red) and anti-hPEDF
(green) antibodies. (A) Orthogonal projection of RPE cells
localized between RPE and ONL. (B–E) RPE cells
immunostained with PEDF and His in detail at super-
resolution confocal microscopy. Arrows indicate the cell
group observed. DAPI (blue)-labeled nuclei. Scale bar:
50 mm. (F) No changes in the expression of rPEDF
mRNA in RPE cells. (G) Expression of hPEDF mRNA in
IPE cells with a significant increase in the 5,000 IPE-
PEDF-SB group versus saline-injected eye. (H and I)
Expression of hPEDF mRNA in RPE-PEDF-SB cells (H)
and IPE-PEDF-SB cells (I). The increase of the hPEDF
was significantly high in the 10,000 RPE/IPE-PEDF-SB
group versus all groups in RPE cells (p < 0.001) and
versus saline-injected eye in IPE cells (p < 0.001). Data
are presented as mean ± SEM (n = 4) (*p < 0.05, ***p <
0.001). AU, arbitrary units; GCL, ganglion cell layer; His,
histidine; hPEDF, human pigment epithelium-derived
factor; INL, inner nuclear layer; ONL, outer nuclear layer;
PEDF, pigment epithelium-derived factor; RPE, retinal
pigment epithelium; rPEDF, rat pigment epithelium-
derived factor.
Molecular Therapy: Methods & Clinical Developmentthose differences did not reach statistical significance (Figures 4M–
4P). This result is consistent with the known limitations of this
CNV model.32
The specific Iba1 and CD68markers are expressed in activatedmicro-
glia and macrophages, respectively, in tissues with inflammation,36
whereas apoptotic cells are caspase-3 positive. Anatomical observa-
tions and fluorescence quantification following transplantation at
days 7 and 14 indicated that microglial activation (Iba1) and macro-
phage infiltration (CD68) were not statistically different in rats in-
jected with tRPE/IPE-PEDF-SB and tRPE/IPE-PEDF groups (Figures
S3A–S3D; Figures 5A–5D). After 14 days post-laser treatment, we
observed an increase in Iba1 and CD68 expression in animals trans-
planted with 5,000 and 10,000 RPE-PEDF-SB (Figures 5C and 5E)
and IPE-PEDF-SB cells (Figures 5D and 5F); however, this increase
was not statistically significant. At 7 and 14 days after laser photoco-
agulation, no changes in caspase-3-positive cells were found in the
outer nuclear layer (ONL) of injection-treated retinas versus saline-
injected eye (Figures S3E–S3H).
Close-to-RandomProfile of SB-Mediated Transgene Integration
in rRPE and rIPE Cells
Insertions of therapeutic foreign DNA into the genome are subject to
position effects, whichmay alter cell physiology and lead tomalignant406 Molecular Therapy: Methods & Clinical Development Vol. 15 December 2019transformations. Consistent with the results
obtained in other cell types,37,44,45 the SB trans-
poson system exhibits a close-to-random profile
of genomic integration in therapeutically rele-vant human T cells46–48 and CD34+ hematopoietic stem and progen-
itor cells (HSPCs).49,50
In order to assess the relative safety of SB transposon-mediated gene
delivery in the context of the here described in vivo AMD gene ther-
apy model, we analyzed the genome-wide insertion profiles of PEDF
transgene-bearing SB vectors in rRPE and rIPE cells. At the primary
DNA sequence level, TA dinucleotides positioned at the center of an
8-bp palindromic AT repeat, a canonical molecular signature of SB
chromosomal integration,47 were found to be the preferred sites of
SB integration in rat cells (Figure 6A). In agreement with earlier find-
ings, we found that SB insertions show only a minor bias toward
actively transcribed genes and a depletion in exon sequences and 50
UTRs (Figure 6B). As in other cell types, we found a slight correlation
between insertion frequencies and the relative transcriptional activ-
ities at the insertion sites (Figure S4).
Integration of therapeutic gene constructs into genomic “safe har-
bors” (GSHs) in the human genome would prevent insertional muta-
genesis and associated risks of oncogenesis in gene therapy. GSHs are
regions of the human genome that support predictable expression of
newly integrated DNA without adverse effects on the host cell. GSHs
can be bioinformatically allocated to chromosomal sites or regions if
they satisfy the following criteria: (1) distance of at least 50 kb from
Figure 3. Analysis of PEDF, VEGF, PEDF/VEGF Ratio, and MMP-2 and -9 Activity Analysis
(A–F) PEDF (A and B) and VEGF (C and D) expression in rats injected with tRPE (A, C, and E) and IPE (tIPE) cells (B, D, and F) (5,000 and 10,000 PEDF-SB and 10,000
PEDF cells) versus saline injection. PEDF and VEGF expression ratio (E and F) in rats injected with tRPE (E) and tIPE (F) cells (5,000 and 10,000 PEDF-SB and 10,000
PEDF cells) versus saline injection. (G–J) MMP-2 (G and H) andMMP-9 (I and J) activity in homogenates from rat eyes injected with tRPE (G and I) and IPE (tIPE) cells (H and J)
(5,000 and 10,000 PEDF-SB and 10,000 PEDF cells) versus saline injection. PEDF expression (A) and PEDF/VEGF ratio (E) were significantly increased in rats injected
with RPE-10,000 PEDF-SB, whereas no changes in VEGF expression were observed. MMP-2 expression was significantly decreased in rats injected with RPE-10,000
PEDF-SB (G), whereas no changes inMMP-9were observed. Data are presented as percentage of AUmean ±SEM (n = 5) (*p < 0.05 versus Saline). AU, arbitrary units; MMP,
metalloproteinase; PEDF, pigment epithelium-derived factor; tIPE, transfected iris pigment epithelial (cells); tRPE, transfected retinal pigment epithelial (cells); VEGF, vascular
endothelial growth factor.
www.moleculartherapy.orgthe 50 end of any gene; (2) distance of at least 300 kb from any cancer-
related gene (see above); (3) distance of at least 300 kb from any
microRNA (miRNA) gene; (4) location outside transcription units;
and (5) location outside ultra-conserved regions (UCRs) of the rat
genome.47,51 The SB insertion sites in rat retinal cells occur at
GSHs at a frequency of 33% (Figure 6C), which was in line with pre-
vious observations in human T cells,48 HSPCs, as well as human RPE
cells.49,50 Collectively, our analysis on vector biosafety predicts a
favorable transgene insertion profile of SB for therapeutic gene trans-
fer in RPE and IPE cells.
DISCUSSION
Here we demonstrate that transplantation of genetically modified
RPE and IPE cells using pFAR4 plasmids encoding the SB100X trans-Molecular Theposase overexpressing PEDF prevents and suppresses vessel leakage
and CNV, and regenerates the natural VEGF/PEDF balance. The
main features that define the severity of the retinal pathology include
vessel leakage, CNV area, and a proangiogenic environment. Leakage
is an indicator of the high permeability and immaturity of vessels that
leak fluid and blood, thus provoking edema, hemorrhages, and finally,
loss of vision.52 The CNV area defines the severity of the disease,
which is dependent on the proangiogenic state of the surrounding
environment. Importantly, alongside the elevated PEDF level, a
decrease of MMP-2 expression is according to the observed antian-
giogenic environment following tIPE and tRPE cell therapy. These re-
sults are consistent with our previous pilot studies showing safety,
effectiveness at a higher single dose, and survival of PEDF-expressing
cells transplanted in the rat subretinal space.31,49,53–58rapy: Methods & Clinical Development Vol. 15 December 2019 407
(legend on next page)
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Figure 5. Iba1 and CD68 Expression
Immunofluorescence Images in CNV Areas 14 Days
after Laser in Rats Injected with tRPE and tIPE Cells
(A–F) Immunofluorescence retinal images (A and B) and
intensity measurements (C–F) of lectin (gray), Iba1 (green),
and CD68 (red) in rats injected with tRPE (A, C, and E)
and tIPE (B, D, and F) cells (5,000 and 10,000 PEDF-SB
and 10,000 PEDF cells) versus saline injection after
14 days post-laser. Nuclei are labeled with DAPI (blue).
Data are presented as percentage mean ± SEM (n = 4).
Scale bar: 100 mm. BM, Bruch’s membrane; GCL,
ganglion cell layer; INL, inner nuclear layer; ONL, outer
nuclear layer; PEDF, pigment epithelium-derived factor;
RPE, retinal pigment epithelium; tIPE, transfected iris
pigment epithelial (cells); tRPE, transfected retinal pigment
epithelial (cells).
www.moleculartherapy.orgThe experimental data allow us to draw two important conclusions
with respect to applying a cell-based gene therapy approach to
AMD. First, transposase-mediated permanent insertion of the
PEDF transgene is effective in reducing CNV, and sustained expres-
sion of PEDF might be a likely key to elicit therapeutically relevant
effects in the context of AMD. This correlates well to what wasFigure 4. Fluorescence Angiography (FA), Analyses of the Leakage Area Lectin Staining in Four CNV
Measurements in All Groups Studied
(A–H) FA images (A, B, E, and F) andmeasurement of the percentage leakage area (C, D, G, and H) at 7 (A–D) and
and G) and tIPE cells (B, D, F, and H) (5,000 and 10,000 PEDF-SB and 10,000 PEDF cells) versus saline injection. (I
measurement of the CNV area (J, L, N, and P) at 7 (I–L) and 14 days (M–P) post-laser in rats injected with tRPE (A, B
PEDF-SB and 10,000 PEDF cells) versus saline injection. Data are presented as percentage mean ± SEM (n = 6)
PEDF, pigment epithelium-derived factor; tIPE, transfected iris pigment epithelial (cells); tRPE, transfected retina
Molecular Therapy: Methods & Clindescribed for the self-replicating episomal vec-
tor pEPito. This alternative, non-viral vehicle
has been shown to efficiently deliver an expres-
sion vector for PEDF for the treatment of dia-
betic retinopathy in a mouse model.59 Second,
although both doses of PEDF-expressing cells
were effective in our experiments, mainly the
higher dose (10,000 cells) was able to signifi-
cantly reduce (1) FA leakage, (2) CNV area,
and (3) MMP-2 activity. Thus, higher doses of
therapeutic cells may be superior for a sustained
benefit, likely because they are more potent to
generate an antiangiogenic environment in the
retina by shifting the balance between pro and
antiangiogenic factors (e.g., VEGF and PEDF).
The role of PEDF in macrophage recruitment is
largely unknown, and we found no changes in
macrophage infiltration, active microglia, and
early apoptosis after laser-induced CNV. Cell
transplantation induced no significant change
in microglia activation at 7 and 14 days post-
laser, but was slightly increased in all groupsanalyzed versus the saline group at 14 days postinjection. This accu-
mulation of subretinal and retinal microglia was in turn associated
with multiple features reminiscent of AMD histopathology, including
local RPE structural changes and CNV formation.60–62Microglia acti-
vation could be due to PEDF release, because PEDF activates micro-
glial metabolism without stimulation and proliferation in cell cultureAreas per Flatmounts, and Analysis of the CNV
14 days (E–H) post-laser in rats injected with tRPE (A, C, E,
–P) Fluorescence lectin-stained images (I, K, M, and O) and
, E, and F) and tIPE cells (C, D, G, and H) (5,000 and 10,000
(**p < 0.01, *p < 0.05 versus Saline). Scale bars: 100 mm.
l pigment epithelial (cells).
ical Development Vol. 15 December 2019 409
Figure 6. Genome-wide Distribution of hPEDF Transgene-Containing
Sleeping Beauty Transposons in rRPE and IPE Cells
(A) Sequence logo representing consensus sequences of SB integration sites. The
logo displays the canonical TA integration sites (marked with arrowheads)
embedded in an AT-rich local sequence environment. (B) Distribution of SB in-
sertions in functional genomic segments. Color intensities depict the degree of
deviation (red for enrichment and blue for depletion) from the expected random
distribution, which was set to 1. (C) Representation of vector insertion sites corre-
sponding to genomic safe harbor criteria. The numbers represent percent values of
all insertions of the corresponding group. Color intensities imply deviation from an
ideal, 100% representation. On the right, the overall frequencies of SB insertion sites
(in red) and random expected frequencies (in gray) in GSHs are shown. IPE, iris
pigment epithelial (cells); PEDF, pigment epithelium-derived factor; RPE, retinal
pigment epithelial (cells).
Molecular Therapy: Methods & Clinical Developmentexperiments.60 Moreover, a minor activation of microglia also occurs
in human induced pluripotent stem cell (hiPSC)-derived RPE allo-
grafts without signs of rejection/toxicity.63
Several preclinical studies over the last few years have made an effort
to transplant RPE cells derived from human embryonic stem cells410 Molecular Therapy: Methods & Clinical Development Vol. 15 Decem(hESCs) in minipigs64,65 and rabbits,66 RPE cells derived from iPSCs
in monkeys,63,67 human fetal RPE xenografts in monkeys,68 and RPE
suspension cells and IPE xenotransplant in The Royal College of
Surgeons (RCS) rats.69–71 The transplanted cells in those studies
maintained local tissue integrity, because cells were found to be well
tolerated in clusters in the subretinal space, and no signs of rejection
were observed for relatively long periods of time from 1 to 6 months.
However, clinical applications of hESC- and hiPSC-derived cells still
need to solve technical limitations and safety barriers, such as genetic
and phenotypic variations, risk of graft rejection due to immune
response, or cancer formation.63,72 In the case of AMD patients,
transplanted RPE-choroid sheets and RPE/IPE cell suspensions
were non-toxic and appeared to survive.73–75 Recently, two multidis-
ciplinary clinical trials have reported preliminary results with RPE
derived from hESCs on a synthetic membrane for dry AMD76 and
wet AMD77 treatment. Both research groups tested subretinal im-
plants, and the preliminary results indicated that hESC-derived
RPE implants are safe, at least in the short-term, and may be a feasible
treatment for AMD.
Building upon research targeting PEDF as a therapeutic factor for
AMD, a number of studies involving gene and cell therapy are being
pursued. Success of PEDF delivery using non-integrating adenoviral
vectors has been limited78 because of the short duration of gene expres-
sion and the adverse effects associated with traditional gene delivery
techniques.79–81 As a consequence, there is a great demand for devel-
oping a treatment that allows for the maintenance of high PEDF level
for an extended period of time. In Europe, a phase Ib/IIa ex vivo gene
therapy clinical trial for long-term expression of PEDF in IPE cells by
combining pFAR4 miniplasmid and SB transposon technologies is
planned and has been submitted for approval to Swiss regulatory au-
thorities Swissmedic31,49,55 (https://www.targetamd.eu/), with all pre-
clinical tests completed.82 Our approach is based on the use of RPE
and IPE cells because they show similar characteristics andmany func-
tions in common. RPE cells express PEDF and secrete it into the inter-
photoreceptor matrix, where it exerts its neurotrophic, antiinflamma-
tory, and antiangiogenic activity.83 Moreover, other studies have
demonstrated that IPE cells of vertebrates are able to maintain an
exceptional plasticity for cell-replacement therapy in many retinal dis-
eases (reviewedbyThumann84), andbyCNV inhibition in rats andpre-
venting thedeathof photoreceptor cells in theRCS ratmodel.85 In addi-
tion, IPE cells can replace lost or damaged RPE in the macular area of
AMD patients.74,86–88 The in vitro and transplantation studies suggest
that IPE cells possess a dormant potential to redifferentiate into a
different phenotype89–91 andmay acquire RPE functionality in the sub-
retinal environment. Given the limitations to obtain RPE and IPE cells
in humans associated to the surgery for the future treatment, we trans-
fected both types of cells with different densities, 5,000 and 10,000 cells.
Surgical iridectomy to isolate IPE cells is a relatively straightforward
procedure and a non-invasive intervention in patients.92
The advantages of using the non-viral SB system include its ability to
support sustained long-term expression of the therapeutic gene, its
relatively safe genome-wide insertion profile, associatedwith the lowerber 2019
Figure 7. Diagram of the Plasmids Used in the Study
and Timeline
(A) Schematic diagram of the various constructs used in
the study: (i) pFAR4 CMV SB100X SV40 plasmid, (ii)
pFAR4-ITRs CMV PEDF BGH plasmid, (iii) pFAR4-ITRs
CMV PEDF-His BGH plasmid, and (iv) pFAR4-ITRs
CAGGS Venus SV40 plasmid. (B) Timing and experi-
mental procedures developed. (C) Animal groups, treat-
ments (cell type, doses, and plasmid), and nomenclature
used in the study. CNV, choroidal neovascularization; D,
day; FA, fluorescein angiography; FM, flatmount; GCL,
ganglion cell layer; Iba-1, anti-ionized calcium-binding
adaptor molecule 1; INL, inner nuclear layer; ONL, outer
nuclear layer; PEDF, pigment epithelium-derived factor;
rIPE, rat iris pigment epithelial (cells); rRPE, rat retinal
pigmented epithelial (cells); tIPE, transfected iris pigment
epithelial (cells); tRPE, transfected retinal pigmented
epithelial (cells); WB, western blot; ZM, zymography.
www.moleculartherapy.orgregulatory burden, and significantly reduced costs of the GMP vector
manufacturing.30 Plasmids are easier and cheaper to produce, ship,
and store.93 In contrast, gammaretroviral and lentiviral vectors
commonly utilized in gene therapy tend to integrate in a non-random
manner. Preferential integrations of gammaretroviral vectors near
transcriptional regulatory elements of active genes94,95 and of lentivi-
ral vectors based toward bodies of genes95 bear an increased genotox-
icity risk already manifested in patients treated with gammaretroviral
vectors by leukemogenesis during early gene therapy clinical trials.96 A
fairly randomprofile of SB integrationsmay offer a safer alternative for
lifelong genetic correction of therapeutically relevant cell types,
including RPE and IPE cells. Further potential advantages of a gene
therapy approach for AMD probably include the simplicity and
reduced costs because of the dispensation of lifelong reinjections of
the anti-VEGFs in patients. Therefore, either alone or combined
with anti-VEGF therapy, the present cell-based non-viral SB100X-
mediated PEDF gene therapy can be considered for AMD patients
as a novel therapy, especially in the field of personalized medicine.
MATERIALS AND METHODS
Vector Components, Construction, and Production of pFAR4
Miniplasmids
Construction of the PEDF transposon plasmid, whose expression
cassette contains the hPEDF gene flanked by SB transposon ITRs,
and stable gene delivery using the hyperactive SB100X transposase
system have been previously reported.31,49,54,55 The schematic dia-Molecular Therapy: Methods & Clingram of the plasmids and constructs used in
the study were shown in Figure 7A.
Isolation, Cultivation of Rat Primary IPE and
RPE Cells, and Transfection of RPE and IPE
Cells
The study was performed according to the Asso-
ciation for Research in Vision and Ophthal-
mology (ARVO) Resolution on the Use of Ani-mals in Ophthalmic and Vision Research and approved by the Ethics
Committee for Animal Research of the University of Navarra (proto-
col approval number 023-13).
BrownNorwaymale rats (8–15 weeks old; Charles River Laboratories,
Wilmington, MA, USA) were used to isolate and cultivate RPE and
IPE cells (n = 45) according to the technical protocol used by Gar-
cia-Garcia et al.31 Prior to use of the cells for transfection, a RPE/
IPE sample was cultured on coverslips for phenotyping confirmation
by immunofluorescence (Figures S1A–S1J). All transfections were
carried out by electroporation with the Neon Transfection System us-
ing the 10 mL Kit (Thermo Fisher Scientific) following the manufac-
turer’s protocol. Electroporation parameters for primary cells were
1,100 V, 20 ms, and 2 pulses. In order to verify the transfection, cells
were transfected with pFAR4-ITRs-CAGGS Venus plasmid, and
tRPE and tIPE cells were observed and photographed by the inverted
microscope (Leica, Microsystems CMS, Wetzlar, Germany) (Figures
S1C, S1D, S1H, and S1I). tRPE and tIPE cells with different plasmids
were directly injected after transfection (Figure 7B).
Laser-Induced CNV Model and Subretinal Injection
Adult Brown Norway rats (Charles River, Wilmington, MA, USA)
were housed in standard cages with 12-h light/dark cycle and food
and water provided ad libitum. Animals were anesthetized with a
mixture of ketamine (75 mg/kg; Imalgene 1000; Merial Laboratories,
Barcelona, Spain) and xylazine (10 mg/kg; Xilagesic 2%; Calierical Development Vol. 15 December 2019 411
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of phenylephrine (7.8 mg/mL; Alcon Cusí, Barcelona, Spain) and tro-
picamide (3 mg/mL; Alcon Cusí) eye drops. CNV lesions were created
by using an 810-nm diode laser (Oculight SLx; Iridex, Buckingham-
shire, UK). Four laser photocoagulation spots (250 mW intensity,
0.05 s, and 75-mm spot size) were placed concentrically around the
optic nerve using a coverslip as a contact lens. Eyes that were assigned
to undergo molecular analyses gene expression, western blot analysis,
and zymographies received 12 laser applications. Rupture of Bruch’s
membrane was confirmed by bubble formation. Laser rupture sites
with hemorrhage or subretinal bleeding at the time of laser applica-
tion were excluded from analysis.32
For subretinal injection, rats were intraperitoneally anesthetized with
a mixture of ketamine and xylazine as previously mentioned to mini-
mize animal suffering. Before transfection of cells, supernatants were
subjected to mycoplasma analysis using the Mycoplasma Detection
Kit (13100-01; Southern Biotech, Birmingham, AL, USA). Only after
a negative result, cells were transfected and suspended in PBS at the
appropriate density to inject the number of cells needed in 5 mL.
Pupils were dilated and double-anesthetic (tetracaine chlorhydrate
1 mg/10 mL and oxybuprocaine chlorhydrate 4 mg/10 mL; Alcon
cusí) eye drops were used to anesthetize the eyes. In brief, eyes were
stabilized using a suture, and the superior conjunctiva and subcon-
junctival tissues were cut to expose the sclera. A hole was made
into the subretinal space using a 27G needle where the cells were in-
jected using a 25G de Juan cannula (Synergetics, O’Fallon, MO, USA)
attached to a 25-mLHamilton syringe (HamiltonMesstchnik, Höchst,
Germany). No suture was placed, and oxytetracycline (Terramicina;
Farmasierra Laboratories, Madrid, Spain) antibiotic was applied. To
evaluate the efficacy of the treatment, 2 days after inducing CNV,
5,000 and 10,000 IPE or RPE cells were transfected with the
pFAR4-ITRs CMV-PEDF-BGH miniplasmid with and without the
SB100X transposase (pFAR4-CMV SB100X SV40) (Figure 7C), ratio
16:1 in a total plasmid concentration of 0.5 mg DNA. After proper tip
positioning, ascertained by a focal whitening of the retina, an equiv-
alent of 5,000 or 10,000 cells (50 mL of cell suspension) was injected
subretinally below the optic nerve head. Animals were euthanized
at 7 and 14 days after injection (n = 6). Saline injection was used as
the control group. The experimental design and groups studied
were identified in Figures 7B and 7C.
FA
At 7 and 14 days after laser coagulation, FA images were generated on
anesthetized rats after intraperitoneal injection of 10% fluorescein so-
dium. After photocoagulation, subretinal injection was confirmed by
identifying retinal bubble formation as previously reported by our
group.31 Images were captured using a digital camera (Topcon TRC
50FX camera; Topcon Corporation, Tokyo, Japan). Leaking fluores-
cein may result from incompetent blood vessels as visible in CNV
or through a diseased RPE that no longer blocks fluorescein leakage
originating from the choroid. Areas of leakage in an FA show gradual
enlargement and blurring of their margins.97 The leakage area (in
pixels) was measured using ImageJ software (NIH, Bethesda, MD,412 Molecular Therapy: Methods & Clinical Development Vol. 15 DecemUSA) by two blinded, independent, trained, and experienced ob-
servers. Mean leakage area was calculated for each study group as pre-
viously described,31,32 and differences between treated and control
animals were assessed.
RNA Isolation and Quantitative Real-Time PCR
To determine the expression of hPEDF and rPEDF mRNA in the
treated eyes, we performed a PCR analysis in retinas transplanted
with 10,000 tRPE/tIPE-PEDF-SB cells. At 5 days post-laser, animals
were sacrificed for molecular analyses. The quantitative real-time
PCRs (n = 3 per study group) were performed in cryogenic eye
cups of anesthetized rats. The posterior pole (including the whole
retina with RPE) was placed in 200 mL Lysis buffer (RNeasy Kit;
QIAGEN, Hilden, Germany) in a reaction tube, immediately homog-
enized by pipetting up and down in a sterile pipette tip for 20 times,
and stored at 20C until RNA isolation. RNA isolation was per-
formed according to the recommendations of the manufacturer
(RNASPIN MINI., 25-0500-71; GE Healthcare, Chicago, IL, USA).
RNA was eluted in RNase-free water (20 mL) and stored at 80C.
The cDNA synthesis was done using Qscript cDNAQuanta BIO pro-
tocol for reverse transcription (QIAGEN). The cDNAwas diluted to a
concentration of 1,000 ng/mL, corresponding to the initially measured
total RNA. hPEDF, rat VEGF, and rPEDF mRNAs were quantified in
eyes of rats using the RTqPCR 7300 system (Applied Biosystem, Fos-
ter City, CA, USA) and Applied Biosystems gene expression assays
(Hs01106934_m1, Rn01511601_m1, and Rn00709999_m1, respec-
tively). Relative quantity of each mRNA was calculated for hPEDF
and rPEDF or rVEGF threshold cycle (Ct) normalized to Ct of Ribo-
somal Protein L30 (RPL30) (Rn00821148_g1) and multiplied by
1E+5 for an easier representation. The results have been determined
with the Relative Quantification software from Applied Biosystems
v.1.2 after analysis of each qPCR plate with the SDS v.2.3 software.
Zymography of MMP-2 and MMP-9
Standard methodology for gelatin zymography was used to detect
MMP activity in eye homogenates samples of animals injected with
tRPE and tIPE cells with or without SB100X as described previ-
ously.32,98 The MMP activation ratio for MMP-2 was calculated as
active MMP intensity/active MMP + proMMP intensity. The
MMP-9 activity was also determined using intensity measurements.
Each zymography assay was repeated at least three times to ensure
accuracy.
Western Blotting for VEGF and PEDF
Five micrograms of eye homogenates samples was mixed with
Laemmli buffer (Bio-Rad, CA, USA), boiled for 5 min, separated on
10%–12% SDS-PAGE gels, and transferred to a nitrocellulose mem-
brane. After blocking with 5% skimmed milk (w/v), 0.1% Tween 20
(w/v) in TBS (1 h, room temperature [RT]), membranes were exposed
to a rat monoclonal anti-VEGF antibody (1:5,000, 512808; Bio-
Legend, San Diego, CA, USA) at RT for 1 h followed by incubation
at RT for 1 h with a horseradish peroxidase (HRP)-conjugated
goat anti-rat immunoglobulin G (IgG)-peroxidase-conjugated anti-
body (1:5,000, 31470; Pierce Biotechnology, Waltham, MA, USA).ber 2019
www.moleculartherapy.orgMembranes were tested for monoclonal anti-PEDF (1:1,000;
MAB1059; Millipore, Burlington, MA, USA) overnight at 4C fol-
lowed by incubation at RT for 2 h with a goat anti-mouse IgG-HRP
(1:10,000; sc2005; Santa Cruz Biotechnology, Dallas, TX, USA). Sig-
nals were detected with an enhanced chemiluminescence (ECL) kit
(ECL western blotting detection kit; GE Healthcare) and captured
with ImageQuant 400 (GE Healthcare). The relative intensities of
the immunoreactive bands were analyzed with ImageQuantTL soft-
ware (GE Healthcare). The loading was verified by Ponceau S red
(Sigma-Aldrich, St. Louis, MO, USA), and the same blot was stripped
and reblotted with an anti-b-actin monoclonal antibody (Sigma-
Aldrich) to normalize the VEGF and PEDF levels.
Choroidal Flatmounts and Neovascularization
Brown Norway rats (n = 6 per study group) were euthanized at 7 and
14 days post-laser. Eyes were enucleated and fixed for 1 h in 4% para-
formaldehyde diluted in PBS at 4C. RPE-choroid-sclera complexes
were microsurgically isolated and incubated with blocking buffer con-
taining PBS, 3% Triton X-100, 0.5% Tween 20, 2% sodium azide, and
1% FBS for 1 h at 4C. Then, they were incubated with biotinylated
isolectin (GS-IB4; Vector Labs, Burlingame, CA, USA) overnight at
RT, and the flatmounts were washed in PBS and incubated in Alexa
Fluor Streptavidin 594 (1:250; S32356; Life Technologies, Carlsbad,
CA, USA). The CNV lesions were captured under a confocal micro-
scope (LSM800; Zeiss, Oberkochen, Germany), and the areas were
measured by Fiji ImageJ software.
Immunofluorescence of Frozen Sections
The eyes of Brown Norway rats (n = 3) were enucleated and fixed for
1 h in 4% paraformaldehyde diluted in phosphate buffer (PB) at 4C.
After incubation, the eyes were washed in PBS and cryoprotected in
30% sucrose solution for 24 h. The tissues were embedded in OCT
compound (Tissue-Tek-Sakura, Leiden, the Netherlands) and stored
at20C. The eyeballs were cut into cross sections at 12–14 mm with
a cryostat (Microm HM550; Thermo Fisher Scientific) and stored at
80C until used.
Three to four retinal sections of the area of neovascularization per
group were chosen. The frozen sections were fixed with 4% parafor-
maldehyde and a 0.3 M glycine solution for 5 min to prevent detach-
ment of the section from the slides. Then, the sections were blocked
with blocking buffer solution as mentioned above. Antibodies for
the triple staining were added: anti-mouse CD68 (1:100; MCA341R;
AbD Serotec, Bio-Rad), anti-ionized calcium-binding adaptor mole-
cule 1 (Iba1), anti-goat Iba1 (1:250; ab5076; Abcam, Cambridge,
UK) or anti-rabbit Iba1 (1:250; CP290A; Biocare, Berkshire, UK),
and anti-rabbit caspase-3 (1:250; ab13847; Abcam), and incubated
overnight at 4C. After washing with PBS, the secondary antibodies,
donkey anti-mouse Alexa Fluor 596 (1:250; A10036; Life Technolo-
gies), anti-donkey anti-goat Alexa Fluor 488 (1:250; A11055; Life
Technologies), and donkey anti-rabbit Alexa Fluor 647 (1:250;
A31573; Life Technologies), were added and incubated for 1 h at
RT. All sections were additionally incubated with isolectin as
mentioned in the flatmount labeling to visualize the neovasculariza-Molecular Thetion. DAPI (Sigma-Aldrich) was used as the nuclear marker. Then
sections were mounted with PBS-glycerol (1:1) and analyzed under
a confocal microscope (LSM800; Zeiss). Quantification of the fluores-
cence images was performed by ImageJ. We used the following for-
mula to measure the total immunofluorescence intensity (TII) per
CNV area image: TII = CNV (ii) BG (ii)/HAA (ii) BG (ii), where
BG represents background, HAA represents healthy adjacent area,
and ii represents immunofluorescence intensity, and compared the
TII mean percentage in the CNV area between analyzed study groups.
The cells immunostained with Iba1 and CD68 in CNV areas were
identified in Figure S2.
Vector Insertion Site Analysis
Genomic DNA was isolated from RPE and IPE cells using the Quick
DNA Kit (Zymo Research, Irvine, CA, USA). We used the procedure
already described48 with the following modifications: 1 mg of DNA
per sample was sonicated with the Covaris M220 ultra-solicitor de-
vice. After end-repair, A-tailing, and linker ligation, the terminal seg-
ments of the SB transposon inverted repeats and their flanking
genomic sequences were amplified in two rounds of PCR. In the first
round, 6 mL of purified ligation reaction was used with 25 pmol of the
primers specific for the linker and for the transposon inverted repeat,
Linker and T-Bal-Long, respectively, with the following conditions:
98C for 30 s; 10 cycles of 98C for 10 s, 72C for 30 s; 15 cycles of
98C for 10 s, ramp to 62C (1C/s) for 30 s, 72C for 30 s, and
72C for 5 min. The nested PCRs performed on 5 mL of the purified
first round PCR products with the PE-nest-ind-N and SB-20-bc-ill-N
primers (where N is the number of the Illumina TruSeq indexes) were
run with the following program: 98C for 30 s; 15 cycles of 98C for
10 s, ramp to 64C (1C/s) for 30 s, 72C for 30 s, and 72C for 5 min.
The primer sequences have already been published.48 After 1.5%
agarose gel separation, the 300–500 bp range of the smears was col-
umn purified and sequenced on HiSeq Illumina instruments at
Genewiz USA.
Bioinformatic Analysis of the Insertion Sites
The quality trimming, filtering, and mapping conditions have been
described elsewhere.48 The readswere aligned onto the rn5 rat genome
using the rn5 with bowtie.99,100 The downstream analyses were per-
formed in the R environment101 with homemade scripts. The compo-
sition and frequencies of the nucleotides at SB insertion sites of the
genome were determined and plotted using the SeqLogo tool. The
annotation of the insertion sites in genic features and in GSHs was
done using the genomation package.102 The random set of 10,000
theoretical insertion sites in the rat genome was generated computa-
tionally. The cancer-related genes represent the rat orthologs of
the human cancer gene set downloaded from the Bushman Lab web-
site (http://www.bushmanlab.org/links/genelists). The orthologous
positions were obtained from Ensembl (http://www.ensembl.org/
biomart/martview/59de4d4d3503246cb451221246ed7978). UCRs of
the rat genomewere arbitrarily determined from the phastCons13way
track for the rn5 assembly retrieved from the University of California
Santa Cruz (UCSC) table browser (http://genome.ucsc.edu/) by
filtering regions with scoresR800. Expressional data on the rat retinalrapy: Methods & Clinical Development Vol. 15 December 2019 413
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expressional dataset obtained from the retinas of 3-month-oldWistar
rats. Non-expressed genes of the retina were defined on the bases of
absence of reads from the genes in the dataset. The expressed genes
were grouped into five sets of the same size according their expression
levels, and insertions were counted in them and compared with a
random expected frequency determined with the random insertion
dataset.
Statistical Analysis
Data are presented as mean ± SEM. Statistical analysis was performed
using SPSS 2.0 (SPSS, Chicago, IL, USA) and GraphPad Prism 5.0
(GraphPad Software, San Diego, CA, USA) programs. In vitro studies
were analyzed applying an ANOVA for repeated measures. For CNV
area results, one-way ANOVA was followed by Bonferroni post hoc
tests for multiple comparisons after confirming normal distribution
of the data. p < 0.05 was considered statistically significant.
SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/10.
1016/j.omtm.2019.10.013.
AUTHOR CONTRIBUTIONS
Conceptualization: P.F.-R., A.G.-L., F.P., M.H., S.R., L.G.-G.; Data
Curation: L.G.-G., M.H., J.B., S.R., P.F.-R., C. Miskey; Funding Acqui-
sition: G.T., A.G.-L., P.F.-R., D.S., Z. Izsvák, Z. Ivics, F.P., S.J.; Inves-
tigation: L.G.-G., S.R., M.H., J.B., P.F.-R., M.K.; Methodology: S.D.,
M.K., C. Miskey, C. Marie, A.S., J.B., J.R.R.-M., S.P.; Resources: Z. Izs-
vák, Z. Ivics, D.S., C. Marie; Supervision: A.G.-L., P.F.-R., F.P., G.T.,
D.S., Z. Ivics, Z. Izsvák.; Writing – Original Draft: L.G.-G., S.R.,
M.H., P.F.-R.; Writing – Review & Editing: M.H., S.R., G.T., A.G.-
L., P.F.-R., D.S., Z. Izsvák, Z. Ivics, F.P., S.J., C. Miskey, C. Marie.
CONFLICTS OF INTEREST
A.G.-L. is a consultant for Thea, Allergan, Bayer, Novartis, and Roche
Laboratories. Z. Izsvák and Z. Ivics are co-inventors on several patents
on Sleeping Beauty transposon technology.
ACKNOWLEDGMENTS
This work was supported by the European Union’s Seventh Frame-
work Programme for research, technological development, and
demonstration (grant agreement no. 305134) and Fundación Jesús
Gangoiti Barrera. Publication costs have been financed by Fundación
Multiópticas (Spain) within a collaborative project with the Univer-
sity of Navarra. L.G.-G. received a predoctoral grant from the Asocia-
ción de Amigos de la Universidad de Navarra, Spain. Z. Izsvák was
funded by European Research Council, ERC Advanced [ERC-2011-
ADG 294742].
REFERENCES
1. Folkman, J., and Ingber, D. (1992). Inhibition of angiogenesis. Semin. Cancer Biol. 3,
89–96.
2. Das, A., and McGuire, P.G. (2003). Retinal and choroidal angiogenesis: pathophys-
iology and strategies for inhibition. Prog. Retin. Eye Res. 22, 721–748.414 Molecular Therapy: Methods & Clinical Development Vol. 15 Decem3. Ohno-Matsui, K., Ito, M., and Tokoro, T. (1996). Subretinal bleeding without
choroidal neovascularization in pathologic myopia. A sign of new lacquer crack for-
mation. Retina 16, 196–202.
4. Askou, A.L. (2014). Development of gene therapy for treatment of age-related mac-
ular degeneration. Acta Ophthalmol. 92 (Thesis3), 1–38.
5. Klein, R., Cruickshanks, K.J., Nash, S.D., Krantz, E.M., Nieto, F.J., Huang, G.H.,
Pankow, J.S., and Klein, B. (2010). The prevalence of age-related macular degener-
ation and associated risk factors. Arch. Ophthalmol 128, 750–758.
6. Klein, R., Klein, B.E.K., and Linton, K.L.P. (1992). Prevalence of age-related macul-
opathy. The Beaver Dam Eye Study. Ophthalmology 99, 933–943.
7. Mehta, S. (2015). Age-Related Macular Degeneration. Prim. Care 42, 377–391.
8. Wong, W.L., Su, X., Li, X., Cheung, C.M.G., Klein, R., Cheng, C.-Y., andWong, T.Y.
(2014). Global prevalence of age-related macular degeneration and disease burden
projection for 2020 and 2040: a systematic review and meta-analysis. Lancet
Glob. Health 2, e106–e116.
9. Bourne, R.R.A., Flaxman, S.R., Braithwaite, T., Cicinelli, M.V., Das, A., Jonas, J.B.,
Keeffe, J., Kempen, J.H., Leasher, J., Limburg, H., et al.; Vision Loss Expert Group
(2017). Magnitude, temporal trends, and projections of the global prevalence of
blindness and distance and near vision impairment: a systematic review and
meta-analysis. Lancet Glob. Health 5, e888–e897.
10. Chakravarthy, U., Harding, S.P., Rogers, C.A., Downes, S.M., Lotery, A.J.,
Wordsworth, S., and Reeves, B.C.; IVAN Study Investigators (2012). Ranibizumab
versus bevacizumab to treat neovascular age-related macular degeneration: one-
year findings from the IVAN randomized trial. Ophthalmology 119, 1399–1411.
11. Martin, D.F., Maguire, M.G., Fine, S.L., Ying, G.S., Jaffe, G.J., Grunwald, J.E., Toth,
C., Redford, M., and Ferris, F.L., 3rd; Comparison of Age-related Macular
Degeneration Treatments Trials (CATT) Research Group (2012). Ranibizumab
and bevacizumab for treatment of neovascular age-related macular degeneration:
two-year results. Ophthalmology 119, 1388–1398.
12. Hollingworth, W., Jones, T., Reeves, B.C., and Peto, T. (2017). A longitudinal study
to assess the frequency and cost of antivascular endothelial therapy, and inequalities
in access, in England between 2005 and 2015. BMJ Open 7, e018289.
13. Klettner, A., Tahmaz, N., Dithmer, M., Richert, E., and Roider, J. (2014). Effects of
aflibercept on primary RPE cells: toxicity, wound healing, uptake and phagocytosis.
Br. J. Ophthalmol. 98, 1448–1452.
14. Saenz-de-Viteri, M., Fernández-Robredo, P., Hernández, M., Bezunartea, J., Reiter,
N., Recalde, S., and García-Layana, A. (2016). Single- and repeated-dose toxicity
study of bevacizumab, ranibizumab, and aflibercept in ARPE-19 cells under normal
and oxidative stress conditions. Biochem. Pharmacol. 103, 129–139.
15. Lois, N., McBain, V., Abdelkader, E., Scott, N.W., and Kumari, R. (2013). Retinal
pigment epithelial atrophy in patients with exudative age-related macular degener-
ation undergoing anti-vascular endothelial growth factor therapy. Retina 33, 13–22.
16. Carmeliet, P., De Smet, F., Loges, S., and Mazzone, M. (2009). Branching morpho-
genesis and antiangiogenesis candidates: tip cells lead the way. Nat. Rev. Clin. Oncol.
6, 315–326.
17. Saint-Geniez, M., Maharaj, A.S.R., Walshe, T.E., Tucker, B.A., Sekiyama, E.,
Kurihara, T., Darland, D.C., Young, M.J., and D’Amore, P.A. (2008). Endogenous
VEGF is required for visual function: evidence for a survival role on müller cells
and photoreceptors. PLoS One 3, e3554.
18. Brar, V.S., Sharma, R.K., Murthy, R.K., and Chalam, K.V. (2010). Bevacizumab neu-
tralizes the protective effect of vascular endothelial growth factor on retinal ganglion
cells. Mol. Vis. 16, 1848–1853.
19. Falero-Perez, J., Park, S., Sorenson, C.M., and Sheibani, N. (2017). PEDF expression
affects retinal endothelial cell proangiogenic properties through alterations in cell
adhesive mechanisms. Am. J. Physiol. Cell Physiol. 313, C405–C420.
20. Zhang, S.X., Wang, J.J., Gao, G., Parke, K., and Ma, J.X. (2006). Pigment epithelium-
derived factor downregulates vascular endothelial growth factor (VEGF) expression
and inhibits VEGF-VEGF receptor 2 binding in diabetic retinopathy. J. Mol.
Endocrinol. 37, 1–12.
21. Tombran-Tink, J., and Barnstable, C.J. (2003). PEDF: a multifaceted neurotrophic
factor. Nat. Rev. Neurosci. 4, 628–636.ber 2019
www.moleculartherapy.org22. Tombran-Tink, J., Chader, G.G., and Johnson, L.V. (1991). PEDF: a pigment epithe-
lium-derived factor with potent neuronal differentiative activity. Exp. Eye Res. 53,
411–414.
23. Ek, E.T.H., Dass, C.R., and Choong, P.F. (2006). Pigment epithelium-derived factor:
a multimodal tumor inhibitor. Mol. Cancer Ther. 5, 1641–1646.
24. Amaral, J., Fariss, R.N., Campos, M.M., Robison, W.G., Jr., Kim, H., Lutz, R., and
Becerra, S.P. (2005). Transscleral-RPE permeability of PEDF and ovalbumin pro-
teins: implications for subconjunctival protein delivery. Invest. Ophthalmol. Vis.
Sci. 46, 4383–4392.
25. Hussain, R.M., and Ciulla, T.A. (2017). Emerging vascular endothelial growth factor
antagonists to treat neovascular age-related macular degeneration. Expert Opin.
Emerg. Drugs 22, 235–246.
26. Narayanavari, S.A., Chilkunda, S.S., Ivics, Z., and Izsvák, Z. (2017). Sleeping
Beauty transposition: from biology to applications. Crit. Rev. Biochem. Mol. Biol.
52, 18–44.
27. Kebriaei, P., Izsvák, Z., Narayanavari, S.A., Singh, H., and Ivics, Z. (2017).
Gene Therapy with the Sleeping Beauty Transposon System. Trends Genet. 33,
852–870.
28. Hodge, R., Narayanavari, S.A., Izsvák, Z., and Ivics, Z. (2017). Wide Awake and
Ready to Move: 20 Years of Non-Viral Therapeutic Genome Engineering with the
Sleeping Beauty Transposon System. Hum. Gene Ther. 28, 842–855.
29. Hudecek, M., Izsvák, Z., Johnen, S., Renner, M., Thumann, G., and Ivics, Z. (2017).
Going non-viral: the Sleeping Beauty transposon system breaks on through to the
clinical side. Crit. Rev. Biochem. Mol. Biol. 52, 355–380.
30. Hudecek, M., and Ivics, Z. (2018). Non-viral therapeutic cell engineering with the
Sleeping Beauty transposon system. Curr. Opin. Genet. Dev. 52, 100–108.
31. Garcia-Garcia, L., Recalde, S., Hernandez, M., Bezunartea, J., Rodriguez-Madoz, J.R.,
Johnen, S., Diarra, S., Marie, C., Izsvák, Z., Ivics, Z., et al. (2017). Long-Term PEDF
Release in Rat Iris and Retinal Epithelial Cells after Sleeping Beauty Transposon-
Mediated Gene Delivery. Mol. Ther. Nucleic Acids 9, 1–11.
32. Ivanescu, A.A., Fernández-Robredo, P., Heras-Mulero, H., Sádaba-Echarri, L.M.,
García-García, L., Fernández-García, V., Moreno-Orduna, M., Redondo-Exposito,
A., Recalde, S., and García-Layana, A. (2015). Modifying choroidal neovasculari-
zation development with a nutritional supplement in mice. Nutrients 7, 5423–
5442.
33. Zarranz-Ventura, J., Fernández-Robredo, P., Recalde, S., Salinas-Alamán, A.,
Borrás-Cuesta, F., Dotor, J., and García-Layana, A. (2013). Transforming growth
factor-beta inhibition reduces progression of early choroidal neovascularization le-
sions in rats: P17 and P144 peptides. PLoS ONE 8, e65434.
34. Recalde, S., Zarranz-Ventura, J., Fernández-Robredo, P., García-Gómez, P.J.,
Salinas-Alamán, A., Borrás-Cuesta, F., Dotor, J., and García-Layana, A. (2011).
Transforming growth factor-b inhibition decreases diode laser-induced choroidal
neovascularization development in rats: P17 and P144 peptides. Invest.
Ophthalmol. Vis. Sci. 52, 7090–7097.
35. Ebrahem, Q., Qi, J.H., Sugimoto, M., Ali, M., Sears, J.E., Cutler, A., Khokha, R.,
Vasanji, A., and Anand-Apte, B. (2011). Increased neovascularization in mice lack-
ing tissue inhibitor of metalloproteinases-3. Invest. Ophthalmol. Vis. Sci. 52, 6117–
6123.
36. Huang, H., Parlier, R., Shen, J.K., Lutty, G.A., and Vinores, S.A. (2013). VEGF
Receptor Blockade Markedly Reduces Retinal Microglia/Macrophage Infiltration
into Laser-Induced CNV. PLoS One 8, e71808.
37. Vigdal, T.J., Kaufman, C.D., Izsvák, Z., Voytas, D.F., and Ivics, Z. (2002). Common
physical properties of DNA affecting target site selection of sleeping beauty and
other Tc1/mariner transposable elements. J. Mol. Biol. 323, 441–452.
38. Hollborn, M., Stathopoulos, C., Steffen, A., Wiedemann, P., Kohen, L., and
Bringmann, A. (2007). Positive feedback regulation between MMP-9 and VEGF
in human RPE cells. Invest. Ophthalmol. Vis. Sci. 48, 4360–4367.
39. Jonas, J.B., Tao, Y., Neumaier, M., and Findeisen, P. (2012). Cytokine concentration
in aqueous humour of eyes with exudative age-related macular degeneration. Acta
Ophthalmol. 90, e381–e388.
40. Lamoreaux, W.J., Fitzgerald, M.E., Reiner, A., Hasty, K.A., and Charles, S.T. (1998).
Vascular endothelial growth factor increases release of gelatinase A and decreasesMolecular Therelease of tissue inhibitor of metalloproteinases by microvascular endothelial cells
in vitro. Microvasc. Res. 55, 29–42.
41. Burbridge, M.F., Cogé, F., Galizzi, J.P., Boutin, J.A., West, D.C., and Tucker, G.C.
(2002). The role of the matrix metalloproteinases during in vitro vessel formation.
Angiogenesis 5, 215–226.
42. Wary, K.K., Thakker, G.D., Humtsoe, J.O., and Yang, J. (2003). Analysis of VEGF-
responsive genes involved in the activation of endothelial cells. Mol. Cancer 2, 25.
43. Notari, L., Miller, A., Martínez, A., Amaral, J., Ju, M., Robinson, G., Smith, L.E., and
Becerra, S.P. (2005). Pigment epithelium-derived factor is a substrate for matrix
metalloproteinase type 2 and type 9: implications for downregulation in hypoxia.
Invest. Ophthalmol. Vis. Sci. 46, 2736–2747.
44. Ammar, I., Gogol-Döring, A., Miskey, C., Chen, W., Cathomen, T., Izsvák, Z., and
Ivics, Z. (2012). Retargeting transposon insertions by the adeno-associated virus Rep
protein. Nucleic Acids Res. 40, 6693–6712.
45. Voigt, K., Gogol-Döring, A., Miskey, C., Chen, W., Cathomen, T., Izsvák, Z., and
Ivics, Z. (2012). Retargeting sleeping beauty transposon insertions by engineered
zinc finger DNA-binding domains. Mol. Ther. 20, 1852–1862.
46. Huang, X., Guo, H., Tammana, S., Jung, Y.-C., Mellgren, E., Bassi, P., Cao, Q., Tu,
Z.J., Kim, Y.C., Ekker, S.C., et al. (2010). Gene transfer efficiency and genome-wide
integration profiling of Sleeping Beauty, Tol2, and piggyBac transposons in human
primary T cells. Mol. Ther. 18, 1803–1813.
47. Gogol-Döring, A., Ammar, I., Gupta, S., Bunse, M., Miskey, C., Chen, W., Uckert,
W., Schulz, T.F., Izsvák, Z., and Ivics, Z. (2016). Genome-wide Profiling Reveals
Remarkable Parallels Between Insertion Site Selection Properties of the MLV
Retrovirus and the piggyBac Transposon in Primary Human CD4(+) T Cells.
Mol. Ther. 24, 592–606.
48. Monjezi, R., Miskey, C., Gogishvili, T., Schleef, M., Schmeer, M., Einsele, H., Ivics,
Z., and Hudecek, M. (2017). Enhanced CAR T-cell engineering using non-viral
Sleeping Beauty transposition from minicircle vectors. Leukemia 31, 186–194.
49. Thumann, G., Harmening, N., Prat-Souteyrand, C., Marie, C., Pastor, M., Sebe, A.,
Miskey, C., Hurst, L.D., Diarra, S., Kropp, M., et al. (2017). Engineering of PEDF-
Expressing Primary Pigment Epithelial Cells by the SB Transposon System
Delivered by pFAR4 Plasmids. Mol. Ther. Nucleic Acids 6, 302–314.
50. Holstein, M., Mesa-Nuñez, C., Miskey, C., Almarza, E., Poletti, V., Schmeer, M.,
Grueso, E., Ordóñez Flores, J.C., Kobelt, D., Walther, W., et al. (2018). Efficient
Non-viral Gene Delivery into Human Hematopoietic Stem Cells by Minicircle
Sleeping Beauty Transposon Vectors. Mol. Ther. 26, 1137–1153.
51. Sadelain, M., Papapetrou, E.P., and Bushman, F.D. (2011). Safe harbours for the
integration of new DNA in the human genome. Nat. Rev. Cancer 12, 51–58.
52. Grossniklaus, H.E., and Green, W.R. (2004). Choroidal neovascularization. Am. J.
Ophthalmol. 137, 496–503.
53. Izsvák, Z., and Ivics, Z. (2004). Sleeping beauty transposition: biology and applica-
tions for molecular therapy. Mol. Ther. 9, 147–156.
54. Johnen, S., Djalali-Talab, Y., Kazanskaya, O., Möller, T., Harmening, N., Kropp, M.,
Izsvák, Z., Walter, P., and Thumann, G. (2015). Antiangiogenic and Neurogenic
Activities of Sleeping Beauty-Mediated PEDF-Transfected RPE Cells In Vitro and
In Vivo. BioMed Res. Int. 2015, 863845.
55. Pastor, M., Johnen, S., Harmening, N., Quiviger, M., Pailloux, J., Kropp, M., Walter,
P., Ivics, Z., Izsvák, Z., Thumann, G., et al. (2018). The Antibiotic-free pFAR4 Vector
Paired with the Sleeping Beauty Transposon System Mediates Efficient Transgene
Delivery in Human Cells. Mol. Ther. Nucleic Acids 11, 57–67.
56. Ivics, Z., and Izsvák, Z. (2015). Sleeping Beauty transposition. In Mobile DNA III, N.
Craig, M. Chandler, M. Gellert, A. Lambowitz, P. Rice, and S. Sandmeyer, eds. (ASM
Press). https://doi.org/10.1128/microbiolspec.mdna3-0042-2014.
57. Ivics, Z., and Izsvák, Z. (2011). Nonviral gene delivery with the sleeping beauty trans-
poson system. Hum. Gene Ther. 22, 1043–1051.
58. Johnen, S., Izsvák, Z., Stöcker, M., Harmening, N., Salz, A.K., Walter, P., and
Thumann, G. (2012). Sleeping Beauty transposon-mediated transfection of retinal
and iris pigment epithelial cells. Invest. Ophthalmol. Vis. Sci. 53, 4787–4796.
59. Calado, S.M., Diaz-Corrales, F., and Silva, G.A. (2016). pEPito-driven PEDF
Expression Ameliorates Diabetic Retinopathy Hallmarks. Hum. Gene Ther.
Methods 27, 79–86.rapy: Methods & Clinical Development Vol. 15 December 2019 415
Molecular Therapy: Methods & Clinical Development60. Sugita, Y., Becerra, S.P., Chader, G.J., and Schwartz, J.P. (1997). Pigment epithelium-
derived factor (PEDF) has direct effects on the metabolism and proliferation of mi-
croglia and indirect effects on astrocytes. J. Neurosci. Res. 49, 710–718.
61. Combadière, C., Feumi, C., Raoul, W., Keller, N., Rodéro, M., Pézard, A., Lavalette,
S., Houssier, M., Jonet, L., Picard, E., et al. (2007). CX3CR1-dependent subretinal
microglia cell accumulation is associated with cardinal features of age-related mac-
ular degeneration. J. Clin. Invest. 117, 2920–2928.
62. Tuo, J., Bojanowski, C.M., Zhou, M., Shen, D., Ross, R.J., Rosenberg, K.I., Cameron,
D.J., Yin, C., Kowalak, J.A., Zhuang, Z., et al. (2007). Murine ccl2/cx3cr1 deficiency
results in retinal lesions mimicking human age-related macular degeneration.
Invest. Ophthalmol. Vis. Sci. 48, 3827–3836.
63. Sugita, S., Iwasaki, Y., Makabe, K., Kamao, H., Mandai, M., Shiina, T., Ogasawara,
K., Hirami, Y., Kurimoto, Y., and Takahashi, M. (2016). Successful
Transplantation of Retinal Pigment Epithelial Cells from MHC Homozygote
iPSCs in MHC-Matched Models. Stem Cell Reports 7, 635–648.
64. Koss, M.J., Falabella, P., Stefanini, F.R., Pfister, M., Thomas, B.B., Kashani, A.H.,
Brant, R., Zhu, D., Clegg, D.O., Hinton, D.R., and Humayun, M.S. (2016).
Subretinal implantation of a monolayer of human embryonic stem cell-derived
retinal pigment epithelium: a feasibility and safety study in Yucatán minipigs.
Graefes Arch. Clin. Exp. Ophthalmol. 254, 1553–1565.
65. Brant Fernandes, R.A., Koss, M.J., Falabella, P., Stefanini, F.R., Maia, M., Diniz, B.,
Ribeiro, R., Hu, Y., Hinton, D., Clegg, D.O., et al. (2016). An Innovative Surgical
Technique for Subretinal Transplantation of Human Embryonic Stem Cell-
Derived Retinal Pigmented Epithelium in Yucatan Mini Pigs: Preliminary Results.
Ophthalmic Surg. Lasers Imaging Retina 47, 342–351.
66. Ilmarinen, T., Hiidenmaa, H., Kööbi, P., Nymark, S., Sorkio, A., Wang, J.H., Stanzel,
B.V., Thieltges, F., Alajuuma, P., Oksala, O., et al. (2015). Ultrathin Polyimide
Membrane as Cell Carrier for Subretinal Transplantation of Human Embryonic
Stem Cell Derived Retinal Pigment Epithelium. PLoS One 10, e0143669.
67. Kamao, H., Mandai, M., Okamoto, S., Sakai, N., Suga, A., Sugita, S., Kiryu, J., and
Takahashi, M. (2014). Characterization of human induced pluripotent stem cell-
derived retinal pigment epithelium cell sheets aiming for clinical application.
Stem Cell Reports 2, 205–218.
68. Berglin, L., Gouras, P., Sheng, Y., Lavid, J., Lin, P.K., Cao, H., and Kjeldbye, H.
(1997). Tolerance of human fetal retinal pigment epithelium xenografts in monkey
retina. Graefes Arch. Clin. Exp. Ophthalmol. 235, 103–110.
69. Sauvé, Y., Girman, S.V., Wang, S., Keegan, D.J., and Lund, R.D. (2002). Preservation
of visual responsiveness in the superior colliculus of RCS rats after retinal pigment
epithelium cell transplantation. Neuroscience 114, 389–401.
70. Thumann, G., Salz, A.K., Walter, P., and Johnen, S. (2009). Preservation of photo-
receptors in dystrophic RCS rats following allo- and xenotransplantation of IPE
cells. Graefes Arch. Clin. Exp. Ophthalmol. 247, 363–369.
71. Zhao, C., Boles, N.C., Miller, J.D., Kawola, S., Temple, S., Davis, R.J., and Stern, J.H.
(2017). Development of a Refined Protocol for Trans-scleral Subretinal
Transplantation of Human Retinal Pigment Epithelial Cells into Rat Eyes. J. Vis.
Exp. 126, e55220.
72. Carr, A.-J.F., Smart, M.J.K., Ramsden, C.M., Powner, M.B., da Cruz, L., and Coffey,
P.J. (2013). Development of human embryonic stem cell therapies for age-related
macular degeneration. Trends Neurosci. 36, 385–395.
73. Binder, S., Stolba, U., Krebs, I., Kellner, L., Jahn, C., Feichtinger, H., Povelka, M.,
Frohner, U., Kruger, A., Hilgers, R.D., and Krugluger, W. (2002). Transplantation
of autologous retinal pigment epithelium in eyes with foveal neovascularization re-
sulting from age-related macular degeneration: a pilot study. Am. J. Ophthalmol.
133, 215–225.
74. Aisenbrey, S., Lafaut, B.A., Szurman, P., Hilgers, R.-D., Esser, P., Walter, P., Bartz-
Schmidt, K.U., and Thumann, G. (2006). Iris pigment epithelial translocation in
the treatment of exudative macular degeneration: a 3-year follow-up. Arch.
Ophthalmol. 124, 183–188.
75. Falkner-Radler, C.I., Krebs, I., Glittenberg, C., Povazay, B., Drexler,W., Graf, A., and
Binder, S. (2011). Human retinal pigment epithelium (RPE) transplantation:
outcome after autologous RPE-choroid sheet and RPE cell-suspension in a rando-
mised clinical study. Br. J. Ophthalmol. 95, 370–375.416 Molecular Therapy: Methods & Clinical Development Vol. 15 Decem76. Kashani, A.H., Lebkowski, J.S., Rahhal, F.M., Avery, R.L., Salehi-Had, H., Dang, W.,
Lin, C.M., Mitra, D., Zhu, D., Thomas, B.B., et al. (2018). A bioengineered retinal
pigment epithelial monolayer for advanced, dry age-related macular degeneration.
Sci. Transl. Med 10, eaao4097.
77. da Cruz, L., Fynes, K., Georgiadis, O., Kerby, J., Luo, Y.H., Ahmado, A., Vernon, A.,
Daniels, J.T., Nommiste, B., Hasan, S.M., et al. (2018). Phase 1 clinical study of an
embryonic stem cell-derived retinal pigment epithelium patch in age-related macu-
lar degeneration. Nat. Biotechnol. 36, 328–337.
78. Saishin, Y., Silva, R.L., Saishin, Y., Kachi, S., Aslam, S., Gong, Y.Y., Lai, H., Carrion,
M., Harris, B., Hamilton, M., et al. (2005). Periocular gene transfer of pigment
epithelium-derived factor inhibits choroidal neovascularization in a human-sized
eye. Hum. Gene Ther. 16, 473–478.
79. Yant, S.R., Meuse, L., Chiu, W., Ivics, Z., Izsvak, Z., and Kay, M.A. (2000). Somatic
integration and long-term transgene expression in normal and haemophilic mice
using a DNA transposon system. Nat. Genet. 25, 35–41.
80. Rasmussen, H., Chu, K.W., Campochiaro, P., Gehlbach, P.L., Haller, J.A., Handa,
J.T., Nguyen, Q.D., and Sung, J.U. (2001). Clinical protocol. An open-label, phase
I, single administration, dose-escalation study of ADGVPEDF.11D (ADPEDF) in
neovascular age-related macular degeneration (AMD). Hum. Gene Ther. 12,
2029–2032.
81. Mori, K., Gehlbach, P., Yamamoto, S., Duh, E., Zack, D.J., Li, Q., Berns, K.I., Raisler,
B.J., Hauswirth, W.W., and Campochiaro, P.A. (2002). AAV-mediated gene transfer
of pigment epithelium-derived factor inhibits choroidal neovascularization. Invest.
Ophthalmol. Vis. Sci. 43, 1994–2000.
82. Kropp, M., Harmening, N., Bascuas, T., Sealy, G., Conti, A., Johnen, S., Izsvák, Z.,
Marie, C., Scherman, D., Ronchetti, M., Aranda, P., van den Berg, J., and
Thumann, G. (2018). GMP-grade production of tIPE, a cell-based gene therapy
product to treat neovascular age-related macular degeneration (nvAMD) developed
in the TargetAMD project. Human Gene Therapy 27, A69.
83. Becerra, S.P., Fariss, R.N., Wu, Y.Q., Montuenga, L.M., Wong, P., and Pfeffer, B.A.
(2004). Pigment epithelium-derived factor in the monkey retinal pigment epithe-
lium and interphotoreceptor matrix: apical secretion and distribution. Exp. Eye
Res. 78, 223–234.
84. Thumann, G. (2001). Development and cellular functions of the iris pigment epithe-
lium. Surv. Ophthalmol. 45, 345–354.
85. Semkova, I., Kreppel, F., Welsandt, G., Luther, T., Kozlowski, J., Janicki, H.,
Kochanek, S., and Schraermeyer, U. (2002). Autologous transplantation of geneti-
cally modified iris pigment epithelial cells: a promising concept for the treatment
of age-related macular degeneration and other disorders of the eye. Proc. Natl.
Acad. Sci. USA 99, 13090–13095.
86. Kociok, N., Heppekausen, H., Schraermeyer, U., Esser, P., Thumann, G., Grisanti, S.,
and Heimann, K. (1998). The mRNA expression of cytokines and their receptors in
cultured iris pigment epithelial cells: a comparison with retinal pigment epithelial
cells. Exp. Eye Res. 67, 237–250.
87. Thumann, G., Aisenbrey, S., Schraermeyer, U., Lafaut, B., Esser, P., Walter, P., and
Bartz-Schmidt, K.U. (2000). Transplantation of autologous iris pigment epithelium
after removal of choroidal neovascular membranes. Arch. Ophthalmol. 118, 1350–
1355.
88. Lappas, A., Weinberger, A.W., Foerster, A.M., Kube, T., Rezai, K.A., and Kirchhof,
B. (2000). Iris pigment epithelial cell translocation in exudative age-related macular
degeneration. A pilot study in patients. Graefes Arch. Clin. Exp. Ophthalmol. 238,
631–641.
89. Yasuda, K., Okada, T.S., Eguchi, G., and Hayashi, M. (1978). A demonstration of a
switch of cell type in human fetal eye tissues in vitro: pigmented cells of the iris or the
retina can transdifferentiate into lens. Exp. Eye Res 26, 591–595.
90. Okada, T.S. (1980). Cellular metaplasia or transdifferentiation as a model for retinal
cell differentiation. Curr. Top. Dev. Biol. 16, 349–380.
91. Okada, T.S. (1983). Recent progress in studies of the transdifferentiation of eye tis-
sue in vitro. Cell Differ. 13, 177–183.
92. Wu, Y., Han, F., Quan, Y., Jiang, W., Zhang, H., and Luo, T. (2016). Comparison of
peripheral iridectomy methods for posterior chamber phakic intraocular lens im-
plantation in patients with brown irides. BMC Ophthalmol. 16, 51.ber 2019
www.moleculartherapy.org93. Hardee, C.L., Arévalo-Soliz, L.M., Hornstein, B.D., and Zechiedrich, L. (2017).
Advances in Non-Viral DNA Vectors for Gene Therapy. Genes (Basel) 8, 65.
94. Cattoglio, C., Pellin, D., Rizzi, E., Maruggi, G., Corti, G., Miselli, F., Sartori, D.,
Guffanti, A., Di Serio, C., Ambrosi, A., et al. (2010). High-definition mapping of
retroviral integration sites identifies active regulatory elements in human multipo-
tent hematopoietic progenitors. Blood 116, 5507–5517.
95. Cavazza, A., Moiani, A., and Mavilio, F. (2013). Mechanisms of retroviral integra-
tion and mutagenesis. Hum. Gene Ther. 24, 119–131.
96. Cicalese, M.P., and Aiuti, A. (2015). Clinical applications of gene therapy for pri-
mary immunodeficiencies. Hum. Gene Ther. 26, 210–219.
97. Schatz, H. (1978). Sloughing of skin following fluorescein extravasation. Ann.
Ophthalmol. 10, 625.
98. Fernandez-Robredo, P., Recalde, S., Moreno-Orduña, M., García-García, L.,
Zarranz-Ventura, J., and García-Layana, A. (2013). Azithromycin reduces inflam-
mation in a rat model of acute conjunctivitis. Mol. Vis. 19, 153–165.Molecular The99. Langmead, B., Trapnell, C., Pop, M., and Salzberg, S.L. (2009). Ultrafast and mem-
ory-efficient alignment of short DNA sequences to the human genome. Genome
Biol. 10, R25.
100. Sarver, A.L., Erdman, J., Starr, T., Largaespada, D.A., and Silverstein, K.A.T. (2012).
TAPDANCE: an automated tool to identify and annotate transposon insertion CISs
and associations between CISs from next generation sequence data. BMC
Bioinformatics 13, 154.
101. R Development Core Team. (2008). R: A language and environment for statistical
computing (R Foundation for Statistical Computing).
102. Akalin, A., Franke, V., Vlahovicek, K., Mason, C.E., and Schübeler, D. (2015).
Genomation: a toolkit to summarize, annotate and visualize genomic intervals.
Bioinformatics 31, 1127–1129.
103. Kozhevnikova, O.S., Korbolina, E.E., Ershov, N.I., and Kolosova, N.G. (2013). Rat
retinal transcriptome: effects of aging and AMD-like retinopathy. Cell Cycle 12,
1745–1761.rapy: Methods & Clinical Development Vol. 15 December 2019 417
